Pharmagreen Biotech, Inc. (PHBI) Reaffirms Commitment to Non-Toxic Financing Amid Ongoing Business Development Progress
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) has announced significant progress in its business development efforts, collaborating with a foreign government on a major project. The initiative aims to introduce Pharmagreen's proprietary Standard Organic Non-Spray Cultivation Procedures (SONSCP) to local farmers, promoting sustainable agriculture. The company plans to launch a premium, connoisseur-grade product line for the global market.
Pharmagreen reaffirms its commitment to non-toxic financing, with current operations funded by CEO Peter Wojcik. The company proposes a partnership structure to form a local subsidiary for project execution on a non-dilutive basis. Additionally, Pharmagreen's MaxGenomic® supplement is available on Amazon and the company's online store.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ha annunciato significativi progressi nei suoi sforzi di sviluppo aziendale, collaborando con un governo straniero su un importante progetto. L'iniziativa mira a introdurre le Procedure di Coltivazione Non- Spruzzate Standard Biologiche Proprietarie (SONSCP) di Pharmagreen agli agricoltori locali, promuovendo l'agricoltura sostenibile. L'azienda prevede di lanciare una linea di prodotti premium di alta qualità per il mercato globale.
Pharmagreen riafferma il suo impegno per un finanziamento non tossico, con le attuali operazioni finanziate dal CEO Peter Wojcik. L'azienda propone una struttura di partnership per formare una filiale locale per l'esecuzione del progetto su base non diluitiva. Inoltre, il supplemento MaxGenomic® di Pharmagreen è disponibile su Amazon e nel negozio online dell'azienda.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ha anunciado importantes avances en sus esfuerzos de desarrollo empresarial, colaborando con un gobierno extranjero en un proyecto importante. La iniciativa tiene como objetivo introducir los Procedimientos de Cultivo Orgánico No Aplicado Estándar Propietario (SONSCP) de Pharmagreen a los agricultores locales, promoviendo la agricultura sostenible. La empresa planea lanzar una línea de productos premium de calidad gourmet para el mercado global.
Pharmagreen reafirma su compromiso con financiamiento no tóxico, con las operaciones actuales financiadas por el CEO Peter Wojcik. La compañía propone una estructura de asociación para formar una subsidiaria local para la ejecución del proyecto en una base no dilutiva. Además, el suplemento MaxGenomic® de Pharmagreen está disponible en Amazon y en la tienda en línea de la empresa.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI)는 사업 개발 노력에서 중요한 진전을 발표하며 외국 정부와의 협력을 통해 대규모 프로젝트를 진행하고 있습니다. 이 이니셔티브는 Pharmagreen의 독점 유기농 비 스프레이 재배 절차(SONSCP)를 지역 농민들에게 도입하여 지속 가능한 농업을 촉진하는 것을 목표로 하고 있습니다. 회사는 글로벌 시장을 위한 프리미엄, 고급 제품군 출시를 계획하고 있습니다.
Pharmagreen은 CEO인 Peter Wojcik이 자금을 지원하는 무독성 금융에 대한 약속을 재확인합니다. 회사는 비희석 방식으로 프로젝트 실행을 위한 현지 자회사를 설립하기 위한 파트너십 구조를 제안합니다. 또한, Pharmagreen의 MaxGenomic® 보충제는 Amazon 및 회사의 온라인 상점에서 구입할 수 있습니다.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) a annoncé des progrès significatifs dans ses efforts de développement commercial, en collaborant avec un gouvernement étranger sur un projet majeur. L'initiative vise à introduire les Procédures de Culture Organiques Non Pulvérisées Standard Proprietaires (SONSCP) de Pharmagreen auprès des agriculteurs locaux, tout en promouvant une agriculture durable. L'entreprise prévoit de lancer une gamme de produits premium de haute qualité pour le marché mondial.
Pharmagreen réaffirme son engagement envers un financement non toxique, avec des opérations actuellement financées par le PDG Peter Wojcik. L'entreprise propose une structure de partenariat pour créer une filiale locale pour l'exécution du projet sur une base non dilutive. De plus, le supplément MaxGenomic® de Pharmagreen est disponible sur Amazon et dans la boutique en ligne de l'entreprise.
Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) hat bedeutende Fortschritte bei ihren Geschäftsentwicklungsanstrengungen bekannt gegeben und arbeitet mit einer ausländischen Regierung an einem großen Projekt. Die Initiative zielt darauf ab, die eigenen standardisierten, organischen Anbaumethoden ohne Sprühmittel (SONSCP) von Pharmagreen den lokalen Landwirten vorzustellen, um nachhaltige Landwirtschaft zu fördern. Das Unternehmen plant, eine Premium-Produktlinie für Feinschmecker für den globalen Markt auf den Markt zu bringen.
Pharmagreen bekräftigt sein Engagement für nicht-toxische Finanzierung, wobei die aktuellen Operationen vom CEO Peter Wojcik finanziert werden. Das Unternehmen schlägt eine Partnerschaftsstruktur vor, um eine lokale Tochtergesellschaft zur Durchführung des Projekts auf nicht-dilutiver Basis zu gründen. Darüber hinaus ist das MaxGenomic®-Nahrungsergänzungsmittel von Pharmagreen auf Amazon und im Online-Shop des Unternehmens erhältlich.
- Collaboration with a foreign government on a major agricultural project
- Introduction of proprietary organic cultivation procedures (SONSCP) to local farmers
- Planned launch of a premium, connoisseur-grade product line for the global market
- Non-dilutive financing through proposed partnership structure and local subsidiary
- MaxGenomic® supplement currently available for purchase on Amazon and company's online store
- Current operations funded by CEO, potentially indicating external funding sources
CARSON CITY, NV, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) ("Pharmagreen" or the "Company") is pleased to announce the continued advancement of its business development efforts on a significant project in collaboration with a foreign government. Considerable progress has been made, and the Company is optimistic about the wide-ranging benefits this initiative will bring to all involved parties.
By incorporating Pharmagreen’s proprietary Standard Organic Non-Spray Cultivation Procedures (SONSCP), local farmers will be empowered to elevate their agricultural practices through sustainable, organic techniques. In collaboration with its partners, Pharmagreen plans to introduce a premium, connoisseur-grade product line for the global market. Details of this product line will be shared in a forthcoming series of press releases as new information becomes available.
The partnership between Pharmagreen, the foreign government, and local communities is expected to deliver a variety of substantial benefits, including the adoption of advanced agricultural technologies, regional economic diversification, environmental sustainability, job creation, enhanced tourism, and the production of value-added goods for global markets. Additional advantages include research and development opportunities as well as health and wellness benefits. This project is designed to grow year after year and is intended to be a continuous initiative.
As previously communicated, Pharmagreen has avoided toxic financing options since last year and remains committed to maintaining this stance. The Company’s current operations are being funded by its CEO, Peter Wojcik, a significant shareholder who is focused on continued growth and value creation for Pharmagreen and its shareholders. Mr. Wojcik is committed to ensuring the Company remains in good standing.
To facilitate the execution of this project on a non-dilutive basis, Pharmagreen has proposed a partnership structure to form a local subsidiary, which will serve as the operating entity for the initiative. This project is expected to generate significant sustained revenues and profits, details of which will be shared in future press releases.
In addition, Pharmagreen’s all-natural MaxGenomic® supplement is currently available for purchase on Amazon and through the Company’s online store at www.maxgenomicproducts.com. As previously mentioned, Pharmagreen plans to expand its premium product offerings with the introduction of a connoisseur-level product line for the global market.
Further updates and details will be provided in future announcements.
Peter Wojcik, CEO of Pharmagreen Biotech, Inc., expressed his deep commitment to the company since its inception, stating, "I have been personally dedicated to Pharmagreen from the very beginning. I firmly believe that the strongest foundation for any company lies in robust business development supported by sustainable, non-destructive financing options. When those conditions are not immediately available, it is essential to work even harder to achieve them while remaining adaptable to what is both feasible and sustainable."
About Pharmagreen Biotech, Inc.
Pharmagreen is currently developing its nutraceutical products and is focused on generating revenues from its proprietary blend of therapeutic plants and mushrooms, and nutraceutical wellness products. Utilizing the Company's expertise in cultivation technologies, plant genetics, Pharmagreen's transgenic program uses the newest technology available to research and create nutraceuticals, and daily supplements with the potential to improve lives and address a wide variety of ailing conditions. For further information on the Company, and our website, please visit www.pharmagreen.ca
For company’s online store, please visit:
https://www.amazon.com/MaxGenomicTM-Supplement-Broadspectrum-Wellness-Beneficial/dp/B0C9C656KR
Safe Harbor Statement
This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause the Company's actual results to differ materially from those projected in such forward-looking statements. In particular, factors that could cause actual results to differ materially from those in forward looking statements include: our inability to obtain additional financing on acceptable terms; risk that our products and services will not gain widespread market acceptance; inability to compete with others who provide comparable products; the failure of our technology; the infringement of our technology with proprietary rights of third parties; inability to respond to consumer demands; inability to replace significant customers; seasonal nature of our business.
Forward-looking statements speak only as of the date made and are not guarantees of future performance. We undertake no obligation to publicly update or revise any forward-looking statements. When used in this document, the words "believe," "expect," "anticipate," "estimate," "project," "plan," "should," "intend," "may," "will," "would," "potential," and similar expressions may be used to identify forward-looking statements.
The OTC Markets or any other securities regulatory authority has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release that has been prepared by management.
Contact Information:
Tel: (702) 803 9404
Email: info@pharmagreen.ca
Online Store: www.maxgenomicproducts.com
Corporate Website: www.pharmagreen.ca
FAQ
What is Pharmagreen Biotech's (PHBI) latest business development project?
How is Pharmagreen Biotech (PHBI) financing its current operations?
What products does Pharmagreen Biotech (PHBI) currently offer?
How does Pharmagreen Biotech (PHBI) plan to execute its new project without diluting shares?
